- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-1801
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Monitoring serum HER2 levels in breast cancer patients ; volume:4 ; number:1 ; day:22 ; month:5 ; year:2015 ; pages:1-7 ; date:12.2015
SpringerPlus ; 4, Heft 1 (22.5.2015), 1-7, 12.2015
- Urheber
-
Tchou, Julia
Lam, Lian
Li, Yun Rose
Edwards, Claire
Ky, Bonnie
Zhang, Hongtao
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40064-015-1015-6
- URN
-
urn:nbn:de:101:1-2021090121322214633504
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tchou, Julia
- Lam, Lian
- Li, Yun Rose
- Edwards, Claire
- Ky, Bonnie
- Zhang, Hongtao
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
HER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells
A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer